A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels

Journal of Neurophysiology

Volumn 85, Issue 5, 2001, Pages 2293-2297

  Grolleau, Françoise ^a,c   Gamelin, Laurence ^b   Boisdron Celle, Michèle ^b   Lapied, Bruno ^a   Pelhate, Marcel ^a   Gamelin, Erick ^b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM ION; CARBOPLATIN; CISPLATIN; DICHLORODIAMINOCYCLOHEXANE; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; OXALIC ACID; OXALIPLATIN; PLATINUM DERIVATIVE; SODIUM; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; COCKROACH; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; MALE; NEUROTOXICITY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SODIUM CURRENT;

EID: 0035003714     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.2001.85.5.2293     Document Type: Article

References (24)

1. CVITKOVIC E AND BEKRADDA M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26: 647-662, 1999.
2. EXTRA JM, MARTY M, BRIENZA S, AND MISSET JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25: 13-22, 1998.
3. GAMELIN E, ALLAIN P, MAILLART P, TURCANT A, DELVA R, LORTHOLARY A, AND LARRA F. Long term pharmacokinetic behaviour platinum after cisplatin administration. Cancer Chemother Pharmacol 37: 97-102, 1995.
4. GAMELIN E, LE BOUIL A, BOISDRON-CELLE M, TURCANT A, DELVA R, CAILLEUX A, MAIGRE M, KRIKORIAN A, BRIENZA S, CVITKOVIC E, ROBERT J, LARRA F, AND ALLAIN P. Cumulative pharmacokinetic study of oxaliplatin administered every three weeks combined with 5-fluorouracil to colorectal cancer patients. Clinical Cancer Res 3: 891-899, 1997.
5. GREGG RW, MOLEPO JM, MONPETIT VJA, MIKAEL NZ, REDMOND D, GADIA M, AND STEWART DJ. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues and morphologic evidence of toxicity. J Clin Oncol 10: 795-803, 1992.
6. 2+ currents contribute to the pacemaker mechanism in cockroach dorsal unpaired median neurons. J Neurophysiol 76: 963-976, 1996.
7. GROLLEAU F AND LAPIED B. Dorsal unpaired median neurons in the insect central nervous system: towards a better understanding of the ionic mechanisms underlying spontaneous electrical activity. J Exp Biol 203: 1633-1648, 2000.
8. HAMERS FPT, VAN DER HOOP RG, STEERENBURG PA, NEIJT JP, AND GISPIN WH. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 311: 514-522, 1991.
9. HAMILL OP, MARTY A, NEHER E, SAKMANN B, AND SIGWORTH FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391: 85-100, 1981.
10. HILLE B. Ionic Channels of Excitable Membranes. Sunderland, MA: Sinauer, 1992, p. 1-607.
11. JACOBSEN D AND MCMARTIN KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol 1: 309-334, 1986.
12. LAINÉ-CESSAC P, GAMELIN L, BOISDRON-CELLE M, GIRAULT C, ALLAIN P, AND GAMELIN E. Acute oxaliplatin neurotoxicity dramatically improved with intravenous calcium and magnesium salts. Congrès Annuel de la Soc Franc Pharmacol, Journées de Pharmacovigilance, 1998.
13. LAPIED B, MALÉCOT CO, AND PELHATE M. Patch-clamp study of the properties of the sodium current in cockroach single isolated adult aminergic neurons. J Exp Biol 144: 535-549, 1990.
14. LOUVET C, BLEIBERG H, GAMELIN E, FRANCOIS E, ANDRE T, EXTRA JM, NOLE F, BENSMAINE MA, ITZHAKI M, BRIENZA S, AND CVITKOVIC E. Oxaliplatin synergystic clinical activity with 5-fluorouracil in FU-resistant colorectal cancer patients is independent of FU ± folinic acid schedule. Proc Am Soc Clin Oncol 15: 206, 1996.
15. MACHOVER D, DIAZ-RUBIO E, DE GRAMONT A, SCHILF A, GASTIABURU JJ, BRIENZA S, ITZHAKI M, METZGER G, N'DAW D, VIGNOUD J, ABAD A, FRANÇOIS E, GAMELIN E, MARTY M, SASTRE J, SEITZ JF, AND YCHOU M. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
16. MAULDIN SK, GIBBONS G, WYRICK SD, AND CHANEY SG. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 48: 5136-5144, 1988.
17. MOLLMAN JE. Cisplatin neurotoxicity. N Engl J Med 322: 126-127, 1990.
18. MOLLMAN JE, GLOVER DJ, HOGAN WM, AND FURMAN RE. Cisplatin neuropathy: risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195, 1988.
19. PELHATE M, PICHON Y, AND BEADLE DJ. Cockroach axons and cell bodies: electrical activity. In: Cockroaches as Models for Neurobiology: Applications in Biomedical Research, edited by Masler EP and Rao BR. Boca Raton, FL: CRC, 1990, p. 131-148.
20. RAYMOND E, CHANEY SG, TAAMMA A, AND CVITKOVIC E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053-1071, 1998a.
21. RAYMOND E, FAIVRE S, WOYNAROVSKI JM. AND CHANEY SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25: 4-12, 1998b.
22. SCRENCI D, ER HM, HAMBLEY TW, GALETTIS P, BROUWER W, AND MCKEAGE MJ. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 76: 502-510, 1997.
23. VAN DER HOOP RG, VEEHT CJ, VAN DER BURG MEL, ELDERSON A, BOOGERD W, HEIMANS JJ, VRIES EP, VAN HOUWELINGEN JC, JENNEKENS FGI, GISPEN WH, AND NEIJT JP. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 322: 89-94, 1990.
24. YANG CC, LIAO SC, AND DENG JF. Tetrodotoxin poisoning in Taiwan: an analysis of poison center data. Vet Human Toxicol 38: 282-286, 1996.